Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02581007 · ClinicalTrials.gov registry record · Phase 2
Reduced Intensity Conditioning Transplant Using Haploidentical Donors
A Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, sponsored by Northside Hospital.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT02581007 is a Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia that has completed, run by Northside Hospital. The registered enrollment target is 25 participants, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02581007, a Phase 2 study of Multiple Myeloma and Chronic Lymphocytic Leukemia, has completed, sponsored by Northside Hospital.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of graft rejection and acute GVHD. A secondary objective will be to estimate the incidence of the relapse, NRM, OS, chronic GVHD and EFS.
Conditions Studied
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Melphalan
- PROCEDURE peripheral blood stem cell transplant
Study Locations (1)
Georgia
- Northside Hospital - Atlanta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2015-10-26 |
| Est. Completion | 2020-12-28 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02581007
The ClinicalTrials.gov registry entry for NCT02581007 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 547-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (95% lower). The listed sponsor is Northside Hospital, which has 26 total studies on file at ClinicalTrials.gov.
The record links to 10 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT02581007 reports 1 study location spanning 1 distinct geographic area - top geographies include Georgia.
Frequently Asked Questions
What is clinical trial NCT02581007 about?
NCT02581007 is a clinical study titled "Reduced Intensity Conditioning Transplant Using Haploidentical Donors". This trial will evaluate the safety and efficacy of a reduced intensity allogeneic HSCT from partially HLA-mismatched first-degree relatives utilizing PBSC as the stem cell source. The primary objective of the study is to estimate the incidence of graft rejection and acute GVHD. A secondary objectiv...
What is the current status of trial NCT02581007?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2015-10-26. Estimated completion is 2020-12-28.
What conditions does trial NCT02581007 study?
This clinical trial studies the following conditions: Multiple Myeloma, Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Myelofibrosis.
What interventions are being tested in trial NCT02581007?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Melphalan (DRUG), peripheral blood stem cell transplant (PROCEDURE).
Who is sponsoring clinical trial NCT02581007?
This trial is sponsored by Northside Hospital, which has 26 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02581007 being conducted?
This trial has 1 study location across Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Whether Ide-cel (bb2121) Can Be Made From People With Multiple Myeloma Who Have Had a Hematopoietic Cell Transplant
RECRUITING · Phase 2
-
A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma
RECRUITING · Phase 2
-
Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
CAR T-cell Therapy in Patients With Renal Dysfunction
RECRUITING · Phase 2
-
IMMUNOPLANT for Newly Diagnosed Multiple Myeloma
RECRUITING · Phase 2
-
Nivolumab in Multiple Myeloma Patients After Idecabtagene Vicleucel
RECRUITING · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.